Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy. In this webinar series, you’ll hear from experts and executives from across the life science ecosystem who are poised to help transform healthcare. You’ll learn how these leaders are tackling the many technical and commercial challenges in creating a fundamentally new way of treating patients.
CRISPR in the Clinic: Challenges & Opportunities
Gene editing is having a landmark year, with the recent launch of the first US clinical trial testing a CRISPR-Cas9 treatment, and a second trial set to begin later this year. Biotech and healthcare leaders are closely watching these studies to see what impact CRISPR gene-editing could have on genetic disease, and how possible safety risks, such as unintended edits, might play out in patients. In this webinar, you’ll hear from top CRISPR experts in industry and academia, who will delve into the promise, and the possible pitfalls, of CRISPR-based therapeutics.
Charles Albright, Ph.D.
Chief Scientific Officer
Dr. Matthew Porteus
You've made the cut. Now what? Validation and applications for CRISPR-derived cells
The power of combining CRISPR modifications with the peptide tag, HiBiT, offers new applications in cellular biology, provides understanding of additional disease states and insight into the efficacy of compounds used to treat disease. Current methods of measuring protein abundance are limited due to size, high backgrounds, low sensitivity and lack of function. Often, overexpression can lead to artifacts not inherent to true protein measurements. Combining the speed and simplicity of CRISPR with the versatility and sensitivity of HiBiT allows for the measurement of protein expression at endogenous levels, making HiBiT well suited for CRISPR-mediated genome editing. Here, we will discuss applications for the generation of HiBiT CRISPR workflows, and the genetic characterization of HiBiT clones, stable pools and cell lines.
Marie Schwinn, Ph.D.
Senior Research Scientist II
Advanced Technologies Group